# Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)

> **NCT00947388** · PHASE1 · TERMINATED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 9 (actual)

## Conditions studied

- Recurrent Small Lymphocytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Stage III Chronic Lymphocytic Leukemia
- Stage III Small Lymphocytic Lymphoma
- Stage IV Chronic Lymphocytic Leukemia
- Stage IV Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Bendamustine Hydrochloride
- **BIOLOGICAL:** Alemtuzumab

## Key facts

- **NCT ID:** NCT00947388
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-11
- **Primary completion:** 2012-09
- **Final completion:** 2013-03
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** No more eligible patients
- **Last updated:** 2013-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00947388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00947388, "Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00947388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*